Form 4: Trulieve Cannabis Corp. Interim CFO Ryan Blust Reports Stock Option Grant

Interim CFO of Trulieve Cannabis Corp., Ryan Blust, reports the acquisition of stock options exercisable for 78,167 subordinate voting shares.

Summary

• On March 25, 2025, Ryan Blust, the Interim CFO of Trulieve Cannabis Corp., was granted stock options to purchase 78,167 subordinate voting shares.
• The exercise price of the options is $4.03 per share.
• The options become exercisable in three annual installments, vesting on December 1, 2025, December 1, 2026, and December 1, 2027.
• The options expire on March 25, 2032.
• Following the transaction, Blust directly owns 78,167 derivative securities.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral to positive as it incentivizes management. The sentiment is slightly positive as it indicates confidence in the company's future.

Positives

• The grant of stock options to the Interim CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the Interim CFO.

Industry Context

Stock option grants are a common practice in the cannabis industry to incentivize and retain key executives.

Comparison to Industry Standards

• Comparing the vesting schedule and exercise price to similar grants at companies like Curaleaf, Green Thumb Industries, and Canopy Growth would provide a benchmark for assessing the competitiveness of this compensation package.
• Typical vesting schedules in the cannabis industry range from three to four years, with exercise prices often set at or above the current market price at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Interim CFO to improve company performance.
• Employees may see this as a sign of investment in leadership.

Key Dates

Keywords

stock options, Form 4, insider trading, Ryan Blust, Trulieve Cannabis Corp., TRUL, CFO, beneficial ownership